Med­ical mar­i­jua­na has been in the news re­cent­ly as a treat­ment for a va­ri­ety of med­ical con­di­tions, in­clud­ing glau­co­ma, pain and nau­sea from can­cer chemother­a­py treat­ment and oth­er ill­ness­es. Doc­tor of Ori­en­tal Med­i­cine Dr Li­onel May­ers, mean­while, said there are oth­er al­ter­na­tives be­sides med­ical mar­i­jua­na for treat­ing ail­ments and dis­eases, some that are hun­dreds of years old that peo­ple are re­dis­cov­er­ing.

Speak­ing to the Sun­day Guardian from his Soul Mind Body Re­new­al In­sti­tute of­fice in St Au­gus­tine, May­ers said “There are many oth­er al­ter­nate treat­ments and med­i­cines that are used for pa­tients with can­cer, one of them is In­sulin Po­ten­ti­a­tion Ther­a­py (IPT) in which the pa­tient is treat­ed with low-dose chemother­a­py and in­sulin.

“The pa­tient is in­ject­ed with in­sulin pri­or to chemother­a­py in or­der to trick the can­cer cells in­to the ac­tive phase, the ‘feed­ing phase.’

“The new­ly primed can­cer cells are now more per­me­able and un­able to re­ject the chemo af­ter con­sump­tion."

He said some of the treat­ments in­clude Rife and ozone ther­a­py, hyp­nother­a­py, acupunc­ture, TCM (Tra­di­tion­al Chi­nese Med­i­cine) Shi­at­su mas­sage, ther­mog­ra­phy scans and Dark-field mi­croscopy.

He said Amer­i­can sci­en­tist Roy­al Ray­mond Rife in­vent­ed the Rife ma­chine in the 1920s.

May­ers said it pro­duced elec­tro­mag­net­ic fre­quen­cies and Rife cured 16 ter­mi­nal­ly ill pa­tients with var­i­ous can­cers back in 1934.

He said even af­ter Rife’s death in 1971, his work to a large ex­tent was still car­ried on main­ly un­der­ground be­cause the US FDA (Food and Drug Ad­min­is­tra­tion) hadn’t ap­proved it but that hasn’t stopped its use from spread­ing.

May­ers said a good Rife ma­chine can treat at least 100 to 150 dis­eases “quite well” and he did not know of a sin­gle case where he put some­one on the ma­chine and they did not show rapid im­prove­ment.

He said some of the dis­eases the Rife ma­chine treat­ed were can­cer, leukaemia, Non­com­mu­ni­ca­ble dis­eases (NCDs) such as asth­ma and di­a­betes, al­so arthri­tis, Lu­pus, Gi­a­r­dia in­fec­tion, can­di­da, carpal tun­nel syn­drome and cataracts.

May­ers said Jo­han­na Bud­wig, a Ger­man bio­chemist, de­vised a plan to kill can­cer in the 1950s us­ing flaxseed, flaxseed oil and cot­tage cheese which is now re­ferred to as the Bud­wig di­et or pro­to­col.

He said when the flaxseed oil and cot­tage cheese were blend­ed, a chem­i­cal re­ac­tion takes place be­tween the sul­phur pro­tein in the cot­tage cheese and the oil, which makes the oil wa­ter-sol­u­ble for easy ab­sorp­tion in­to a per­son’s cells.

May­ers said cot­tage cheese was rich in sul­phur pro­tein, the same sul­phuric group that was of­ten con­tained in can­cer drugs and sat­u­rat­ed fats, while flaxseed oil was rich in un­sat­u­rat­ed fats.

He said Bud­wig al­so de­vised a Ke­to­genic di­et which used very lit­tle sug­ar to starve can­cer cells and grad­u­al­ly shrink them be­cause they had noth­ing to feed on.

May­ers, a mem­ber of the Amer­i­can Guild of Hyp­nother­a­pists, said the Ke­to­genic di­et was very sim­i­lar to the Mediter­ranean di­et when an epilep­tic pa­tient was put on the di­et, most times the seizures stop af­ter sev­er­al weeks.

He said most of these sim­ple treat­ments from the 30s were ef­fec­tive but were buried.

May­ers said drug com­pa­nies were not in­ter­est­ed in cures; it was more prof­itable to have peo­ple tak­ing pills and med­i­cine for life.

He cit­ed a Gold­man Sachs biotech re­search re­port ‘Is cur­ing pa­tients a sus­tain­able busi­ness mod­el?’ of April 11, 2018, which said cures could be bad for busi­ness.

May­ers said Robert R Bare­foot said in his book Death by Di­et that main­stream med­i­cine, along with the phar­ma­ceu­ti­cal in­dus­try, sup­pressed in­for­ma­tion on the ef­fects of di­et on health, and in par­tic­u­lar the role of cal­ci­um and oth­er min­er­als in pre­vent­ing and treat­ing dis­eases.

He said, how­ev­er, peo­ple around the world were ex­per­i­ment­ing with al­ter­na­tive treat­ments for var­i­ous dis­eases such as nat­ur­al ther­a­pist and nu­tri­tion­ist Wal­ter Last from Aus­tralia.

May­ers said Last de­vel­oped a can­cer pro­to­col to al­ka­lise the body as the first and most im­por­tant step to stop tu­mour growth and pos­si­bly shrink tu­mours.

He said Last knew al­ready for many years that tu­mours need­ed an acidic en­vi­ron­ment to ac­ti­vate the en­zymes to dis­solve and in­vade sur­round­ing con­nec­tive tis­sue.

May­ers said the Aus­tralian re­searched an ex­per­i­men­tal study show­ing the ex­act pH lev­els (acid-al­ka­line bal­ance) at which tu­mours in­vad­ed or shrunk and de­vel­oped his can­cer pro­to­col.

He said Last even re­searched us­ing Boron for cur­ing arthri­tis.

May­ers said as more re­search and ad­vance­ments in tech­nol­o­gy oc­cur, more al­ter­na­tive treat­ments will de­vel­op such as the re­cent in­frared treat­ment for Parkin­son’s.

Near-in­frared light (NIr), a low-lev­el laser or LED (light-emit­ting diode) is a new neu­ro­pro­tec­tive ap­proach be­ing test­ed in labs for use in treat­ing Parkin­son’s dis­ease and nu­mer­ous oth­er dis­eases and con­di­tions such as Alzheimer’s, stroke, and ALS (Amy­otroph­ic Lat­er­al Scle­ro­sis).